Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Chemo in Salivary Gland Cancer
NCT04825938Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2021
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in salivary gland cancer (SGC), sponsored by Sun Yat-sen Memorial Hospital. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT04825938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04825938.